Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2024 16:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

OCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC...
December 12, 2024 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has...
December 06, 2024 09:15 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...
November 19, 2024 08:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer...
November 15, 2024 07:29 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with...
November 06, 2024 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...
October 09, 2024 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

OCALA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that Tom Equels, Chief Executive Officer of AIM, will participate in...
October 03, 2024 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has...
September 30, 2024 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering

OCALA, Fla., Sept. 30, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a...
September 27, 2024 08:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM will...